Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-positive gastric cancer, drawn from the whole corpus: 24 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
HER2 heterogeneity and loss after treatment make a single biopsy unreliable.
No HER2-directed therapy has yet improved cure rates in resectable disease.
Interstitial lung disease with trastuzumab deruxtecan needs early recognition.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 13 changes by month →When this page itself was last checked or edited.
PFS 12.
OS 14.
A milestone in how this cancer is treated.
Confirmed durable responses to trastuzumab deruxtecan in a Western population after progression on trastuzumab.
Higher response rate and longer progression-free survival with pembrolizumab added to trastuzumab and chemotherapy, with benefit concentrated in PD-L1-positive tumours; accelerated approval in May 2021, later limited to PD-L1 combined positive score of 1 or more.